Skip to main content

Ian Johnson

UK molecular diagnostics firm Biofortuna has named Ian Johnson its new chairman, replacing Mark Hurley, who will remain on the board as a non-executive director. Johnson was founder and CEO of Biotrace International. He also is currently non-executive chairman of Celsis Group and Cyprotex, and is an operational advisor for Harwood Private Equity, an investor in Celsis and Cyprotex.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.